Related Experiment Video
Updated: Sep 21, 2025
10:09
Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
3.3K
Avascular necrosis during alectinib treatment: Case report
1Department Medical Oncology, Ege University School of Medicine, Izmir, Turkey.
Summary
Alectinib, a tyrosine kinase inhibitor, is rarely associated with avascular necrosis of the femoral head. This case highlights a potential risk in patients treated with alectinib, necessitating careful monitoring for hip pain.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC) is a target for tyrosine kinase inhibitors (TKIs).
- Alectinib is a second-generation ALK inhibitor used for ALK-positive NSCLC.
Observation:
- A patient on long-term alectinib treatment developed hip pain.
- Avascular necrosis of the femoral head was diagnosed in the patient.
Findings:
- This is the first reported case of avascular necrosis of the femoral head associated with alectinib use.
- Femoral head avascular necrosis is a rare but potential adverse event associated with TKIs.
Implications:
- Clinicians should be aware of the potential risk of femoral head avascular necrosis in patients receiving alectinib.
- Monitoring for hip pain and early diagnosis of avascular necrosis may be crucial in patients treated with alectinib.
